Catalyst
Slingshot members are tracking this event:
Portola (PTLA) Expects BLA Re-Submission in Q2 for Andexxa (Anadexanet Alfa)
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| PTLA |
|
|
||||
Additional Information
Andexanet alfa is being developed as a universal reversal agent for patients anticoagulated with an oral or injectable Factor Xa inhibitor who experience a serious uncontrolled bleeding event or who require urgent or emergent surgery
Slingshot Insights Explained
Catalyst Date
Occurred on:
Aug 03, 2017
Occurred Source:
http://investors.portola.com/phoenix.zhtml?c=198136&p=irol-newsArticle&ID=2291765
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Biologics License Application, Bla, Andexxa, Serious Uncontrolled Bleeding Event, Urgent, Emergent Surgery, Andexanet Alfa
